Related Experiment Video
Updated: Mar 1, 2026

Simplified Reverse Genetics Method to Recover Recombinant Rotaviruses Expressing Reporter Proteins
Published on: April 17, 2020
Generation of Recombinant Ebola Viruses Using Reverse Genetics.
1Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany. allison.groseth@fli.de.
Researchers generated infectious recombinant Ebola viruses using reverse genetics systems. This method allows for creating custom viruses to study Ebola virus biology and develop diagnostic tools and countermeasures.
Area of Science:
- Virology
- Molecular Biology
- Genetics
Background:
- Reverse genetics systems enable the study of virus life cycles.
- Full-length clone systems facilitate the creation of infectious viruses from plasmid-encoded components.
- Recombinant filoviruses are valuable for studying virus biology and developing diagnostics.
Purpose of the Study:
- To describe the generation and characterization of recombinant Ebola viruses.
- To demonstrate the utility of reverse genetics for creating tailor-made filoviruses.
- To explore the potential of tagged viruses for diagnostics and countermeasure screening.
Main Methods:
- Utilizing full-length clone systems for reverse genetics.
- Employing plasmid-encoded ribonucleoprotein (RNP) components for transcription and replication.
- Rescuing recombinant Ebola viruses from cloned cDNA using a T7-driven system.
Main Results:
- Successful generation of infectious recombinant Ebola viruses.
- Demonstrated feasibility of using reverse genetics for filovirus manipulation.
- Characterization of the rescued recombinant viruses.
Conclusions:
- Reverse genetics systems, particularly full-length clone systems, are effective for generating infectious recombinant Ebola viruses.
- These recombinant viruses serve as valuable tools for studying Ebola virus biology.
- Tagged recombinant viruses offer potential for diagnostic applications and screening for novel countermeasures.
More Related Videos
10:11Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
Published on: September 27, 2014
10:03Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
Published on: August 1, 2013